Netramark Holdings, Pentara form partnership

Mr. Swapan Kakumanu reports NETRAMARK ANNOUNCES PARTNERSHIP WITH PENTARA TO DETECT ANOMALOUS SITE AND PARTICIPANT BEHAVIOR AND SAFEGUARD CLINICAL TRIAL INTEGRITY Netramark Holdings Inc. and Pentara Corp. have entered into an agreement. Netramark, in collaboration with Pentara, will be co-branding and launching a novel site intelligence tool as part of a joint initiative to enhance clinical trial integrity through advanced AI-driven anomaly detection. The tool integrates information-theoretic variability, singleton occurrence frequencies and co-association penalties to derive a Paradox Risk score for anomaly detection at the participant level. This enables the detection of anomalous participants and assessment of site-level irregularities. The framework identifies site-level integrity and anomalous risks using only prerandomization data. Undetected data integrity issues can distort efficacy signals and threaten the validity of study conclusions. Pentara has established itself as an industry leader and innovator in degenerative diseases. Pentara's decision to partner with Netramark highlights its determination to leverage the latest innovative technologies to provide its clients with powerful analytical insights that drive clinical decision-making. "We are excited to partner with Netramark, which focuses on the responsible use of AI in clinical trials, and the implementation of regulatory-aligned AI strategies that provide data-driven insights to guide success throughout a trial. Applying this innovative technology demonstrates our commitment to providing high-quality, efficient solutions to our clients that accelerate medical research," commented Suzanne Hendrix, PhD, chief executive officer at Pentara. "This partnership marks a significant milestone for Netramark as we expand opportunities to leverage our AI technology to inform sponsors of potential areas of improvement in their trial design, beyond participant eligibility criteria and into earlier stages of development, such as pretrial site selections and active trial site reporting," shared Dr. Joseph Geraci, PhD, founder, CTO/CSO at Netramark. Netramark's contributions are expected to enable Pentara to pro-actively mitigate early risks and implement scalable monitoring of sites with real-time alerts and targeted audits across trials. This collaboration is intended to enhance confidence in efficacy outcomes with adaptability to heterogeneous clinical trials and will focus on generating validated and explainable insights to optimize future trial design. About Netramark Holdings Inc. Netramark is a company focused on being a leader in the development of generative artificial intelligence (GenAI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. We seek Safe Harbor.